- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6364
Provisional Schedule
- Expected publication:
- 20 August 2025
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Southampton Health Technology Assessment Centre (SHTAC), University of Southampton
Stakeholders
- Companies sponsors
- Amgen (tarlatamab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Roy Castle Lung Cancer Foundation
- Professional groups
- Association of Cancer Physicians
- British Thoracic Oncology Group
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Comparator companies
- Novartis (topotecan)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 22 July 2025 - 05 July 2025 | Final draft guidance |
| 03 June 2025 | Committee meeting: 2 |
| 03 June 2025 | Declaration of interests |
| 28 January 2025 - 18 February 2025 | Draft guidance |
| 08 October 2024 | Committee meeting: 1 |
| 08 October 2024 | Declaration of interests |
| 05 March 2024 | Invitation to participate |
| 22 January 2024 - 05 February 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6364 |
| 22 January 2024 | In progress. Scoping commenced. |
| 22 September 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual